Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease

Study Summary

This study is a randomized, double-blind, placebo controlled clinical study to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of FB102 in adult participants with well controlled (on a strict GFD) CeD following an oral gluten challenge.

Conditions

Celiac Disease

Interventions / Drugs

FB102 Placebo

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment100 participants

Primary Completion—

Lead SponsorForte Biosciences, Inc.

Data Retrieved2026-04-11 04:13:59.421393+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.